Related references
Note: Only part of the references are listed.Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis
Emmanuel Chigutsa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients
Simbarashe P. Zvada et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Redefining Multidrug-Resistant Tuberculosis Based on Clinical Response to Combination Therapy
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity
A. Satyaraddi et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2014)
The pyrazinamide susceptibility breakpoint above which combination therapy fails
Tawanda Gumbo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Correlation between Genotypic and Phenotypic Testing for Resistance to Rifampin in Mycobacterium tuberculosis Clinical Isolates in Haiti: Investigation of Cases with Discrepant Susceptibility Results
Oksana Ocheretina et al.
PLOS ONE (2014)
Re-Evaluation of the Critical Concentration for Ethambutol Antimicrobial Sensitivity Testing on the MGIT 960
Sara Christianson et al.
PLOS ONE (2014)
Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis
Andreas H. Diacon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Approval of a Tuberculosis Drug Based on a Paradoxical Surrogate Measure
Jerry Avorn
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment
Jennifer Ho et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
Jotam G. Pasipanodya et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Pharmacokinetics and Pharmacodynamics of TMC207 and Its N-Desmethyl Metabolite in a Murine Model of Tuberculosis
Marie-Claude Rouan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Feasibility of a Fixed-Dose Regimen of Pyrazinamide and Its Impact on Systemic Drug Exposure and Liver Safety in Patients with Tuberculosis
Tarjinder Sahota et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy
Jotam G. Pasipanodya et al.
CLINICAL INFECTIOUS DISEASES (2012)
Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis
D. A. Williamson et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2012)
In Silico Children and the Glass Mouse Model: Clinical Trial Simulations To Identify and Individualize Optimal Isoniazid Doses in Children with Tuberculosis
Prakash M. Jeena et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future
Jotam Pasipanodya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis
Zahoor Ahmad et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Protein Binding: Do We Ever Learn?
Markus A. Zeitlinger et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Dose-Dependent Activity of Pyrazinamide in Animal Models of Intracellular and Extracellular Tuberculosis Infections
Zahoor Ahmad et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Saturability of Granulocyte Kill of Pseudomonas aeruginosa in a Murine Model of Pneumonia
G. L. Drusano et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
Jakko van Ingen et al.
CLINICAL INFECTIOUS DISEASES (2011)
Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge
J. van Ingen et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2011)
Impact of Burden on Granulocyte Clearance of Bacteria in a Mouse Thigh Infection Model
G. L. Drusano et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Clinical and Toxicodynamic Evidence that High-Dose Pyrazinamide Is Not More Hepatotoxic than the Low Doses Currently Used
Jotam G. Pasipanodya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability
Tawanda Gumbo
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients
Andreas H. Diacon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Efflux-Pump-Derived Multiple Drug Resistance to Ethambutol Monotherapy in Mycobacterium tuberculosis and the Pharmacokinetics and Pharmacodynamics of Ethambutol
Shashikant Srivastava et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model
G. L. Drusano et al.
MBIO (2010)
Drug interaction: focusing on response surface models
Soo-Il Lee
KOREAN JOURNAL OF ANESTHESIOLOGY (2010)
Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs
Sylvain Goutelle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis
Deepak Almeida et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis from Botswana
Sekai Chideya et al.
CLINICAL INFECTIOUS DISEASES (2009)
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Andreas H. Diacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effect of Protein Binding on the Pharmacological Activity of Highly Bound Antibiotics
Stephan Schmidt et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis
R. Rustomjee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears
A. H. Diacon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Isoniazid bactericidal activity and resistance emergence: Integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid
P. R. Donald et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: A new paradigm for optimizing pharmacodynamics to counterselect resistance
Vincent H. Tam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis:: Evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy
Radha K. Shandil et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth
Tawanda Gumbo et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
Neel R. Gandhi et al.
LANCET (2006)
Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance
T Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis
M Weiner et al.
CLINICAL INFECTIOUS DISEASES (2005)
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update
JW Mouton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Isoniazid pharmacokinetics-pharmaco dynamics in an aerosol infection model of tuberculosis
R Jayaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling
T Gumbo et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis
R Jayaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint
GL Drusano et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs
FA Sirgel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
The triple combination indinavir-zidovudine-lamivudine is highly synergistic
S Snyder et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
